Gaofei Ren1, Xiaojun Ma1, Pengfei Jiao2. 1. Department of Endocrinology, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, Henan, China. 2. Department of Respiratory, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, Henan, China.
Abstract
OBJECTIVE: To investigate the effect of liraglutide combined with metformin or acarbose on glucose control in patients with type 2 diabetes mellitus (T2DM) and to analyze the risk factors of gastrointestinal adverse reactions. METHODS: This retrospective study was conducted on 88 T2DM patients who were treated in our hospital from February 2019 to August 2021. The patients were divided into Group A (n=40) and Group B (n=48) according to different treatment methods. Group A was treated with liraglutide and metformin, while Group B was given liraglutide and acarbose. The effects of glucose control (FPG, 2hPG, HbA1c), inflammatory indexes (IL-6, CRP, SAA), fasting C-peptide, 2-h postprandial C-peptide levels and adverse reactions were compared. Afterwards, The risk factors of gastrointestinal adverse reactions were assessed via logistics regression. RESULTS: It was found that the FPG, 2hPG and HbA1c levels after treatment were lower than those before treatment (P<0.05), and the levels in group A were lower than those in group B (P<0.05). The serum IL-6, CRP and SAA levels after treatment were lower than those before treatment (P<0.05), but there was no marked difference between the two groups after treatment (P>0.05). The fasting C-peptide and 2-h postprandial C-peptide levels in group A after treatment were higher than those in group B (P<0.05). Logistics regression analysis revealed that complicated digestive system diseases and combined use of acarbose were independent risk factors. CONCLUSION: Compared with liraglutide and acarbose, liraglutide and metformin has better glucose control effect in T2DM. Although there is no obvious difference in eliminating inflammation, liraglutide combined with acarbose will increase the incidence of gastrointestinal adverse reactions in patients. So, liraglutide combined with metformin is recommended for T2DM treatment. AJTR
OBJECTIVE: To investigate the effect of liraglutide combined with metformin or acarbose on glucose control in patients with type 2 diabetes mellitus (T2DM) and to analyze the risk factors of gastrointestinal adverse reactions. METHODS: This retrospective study was conducted on 88 T2DM patients who were treated in our hospital from February 2019 to August 2021. The patients were divided into Group A (n=40) and Group B (n=48) according to different treatment methods. Group A was treated with liraglutide and metformin, while Group B was given liraglutide and acarbose. The effects of glucose control (FPG, 2hPG, HbA1c), inflammatory indexes (IL-6, CRP, SAA), fasting C-peptide, 2-h postprandial C-peptide levels and adverse reactions were compared. Afterwards, The risk factors of gastrointestinal adverse reactions were assessed via logistics regression. RESULTS: It was found that the FPG, 2hPG and HbA1c levels after treatment were lower than those before treatment (P<0.05), and the levels in group A were lower than those in group B (P<0.05). The serum IL-6, CRP and SAA levels after treatment were lower than those before treatment (P<0.05), but there was no marked difference between the two groups after treatment (P>0.05). The fasting C-peptide and 2-h postprandial C-peptide levels in group A after treatment were higher than those in group B (P<0.05). Logistics regression analysis revealed that complicated digestive system diseases and combined use of acarbose were independent risk factors. CONCLUSION: Compared with liraglutide and acarbose, liraglutide and metformin has better glucose control effect in T2DM. Although there is no obvious difference in eliminating inflammation, liraglutide combined with acarbose will increase the incidence of gastrointestinal adverse reactions in patients. So, liraglutide combined with metformin is recommended for T2DM treatment. AJTR
Authors: M Pulgar Suárez; P Gómez Guedes; M Aguado Díaz; S Menéndez Alvarez; A García Garaboa; I Rodríguez González; C González Peláez Journal: Aten Primaria Date: 2001-02-15 Impact factor: 1.137
Authors: Pouya Saeedi; Inga Petersohn; Paraskevi Salpea; Belma Malanda; Suvi Karuranga; Nigel Unwin; Stephen Colagiuri; Leonor Guariguata; Ayesha A Motala; Katherine Ogurtsova; Jonathan E Shaw; Dominic Bright; Rhys Williams Journal: Diabetes Res Clin Pract Date: 2019-09-10 Impact factor: 5.602
Authors: N E Antonio-Villa; O Y Bello-Chavolla; A Vargas-Vázquez; R Mehta; C A Aguilar-Salinas Journal: Diabet Med Date: 2020-03-25 Impact factor: 4.359
Authors: Willem Wisgerhof; Carolien Ruijgrok; Nicole R den Braver; Karin J Borgonjen-van den Berg; Amber A W A van der Heijden; Petra J M Elders; Joline W J Beulens; Marjan Alssema Journal: PLoS One Date: 2020-06-04 Impact factor: 3.240
Authors: Leena P Bharath; Madhur Agrawal; Grace McCambridge; Dequina A Nicholas; Hatice Hasturk; Jing Liu; Kai Jiang; Rui Liu; Zhenheng Guo; Jude Deeney; Caroline M Apovian; Jennifer Snyder-Cappione; Gregory S Hawk; Rebecca M Fleeman; Riley M F Pihl; Katherine Thompson; Anna C Belkina; Licong Cui; Elizabeth A Proctor; Philip A Kern; Barbara S Nikolajczyk Journal: Cell Metab Date: 2020-05-12 Impact factor: 31.373